Home > EU > EU Commission approves €200m Irish scheme to aid coronavirus-relevant research

EU Commission approves €200m Irish scheme to aid coronavirus-relevant research

Written by Robert McHugh, on 4th Jun 2020. Posted in EU

article headline

It was announced today that the European Commission has approved a €200 million Irish aid scheme to support investment in research and development (R&D), testing and production of products that are relevant to the coronavirus outbreak.

The scheme was approved under the Temporary Framework adopted by the Commission on 19 March 2020, as amended on 3 April 2020 and 8 May 2020.

The aim of the scheme is to enhance and accelerate the development and the production of products directly relevant to the coronavirus outbreak, including vaccines, hospital and medical equipment and medicinal products, as well as the development of innovative processes for an efficient production of such products.

The public support will take the form of direct grants and repayable advances, and will be open to companies with more than ten employees operating in the manufacturing and/or internationally traded services sectors.

Welcoming the scheme, Minister for Business, Enterprise and Innovation, Heather Humphreys  said,  "The challenge of COVID-19 is first and foremost a health emergency and we will continue to prioritise the medical response to the pandemic. The intention of this new scheme is to accelerate the production of vital medicines and potential vaccines, along with essential equipment, used in the fight against COVID-19."

Source: www.businessworld.ie

More articles from EU

image Description

EU urges more G20 cooperation on monetary, fiscal policy against COVID-19 crisis

Read more
image Description

Merkel says EU must prepare for no-deal Brexit

Read more
image Description

EU wants Brexit deal 'but not at any price' as teams head for dinner

Read more
image Description

EU will stand firm against Washington over trade disputes says commissioner

Read more
image Description

Euro zone investor morale up in July but recovery could stall

Read more